Showing 831-840 of 1066 results for "".
- Gingipain Inhibitor Cleared by FDA for Investigation as Potential Treatment for P. gingivalis–Associated Alzheimer Diseasehttps://practicalneurology.com/news/gingipain-inhibitor-cleared-by-fda-for-investigation-as-potential-treatment-for-p-gingivalis-associated-alzheimer-disease/2470347/The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LHP588 (Lighthouse Pharmaceuticals; San Francisco, CA), a next-generation small-molecule gingipain inhibitor under investigation as a potential treatment for Porphyromonas gingivalis&nda
- Tau-Targeting Investigational Antisense Oligonucleotide Therapy Associated with Favorable Cognition and Clinical Trends in Alzheimer Diseasehttps://practicalneurology.com/news/tau-targeting-investigational-antisense-oligonucleotide-therapy-associated-with-favorable-cognition-and-clinical-trends-in-alzheimer-disease/2470326/Newly reported data related to a study of an investigational antisense oligonucleotide (ASO) therapy BIIB080 (Biogen; Cambridge, MA) showed favorable outcomes for multiple endpoints of cognition and activities of daily living in Alzheimer disease (AD). BIIB080 is designed to target the microtubul
- Emgality Treatment for Migraine Prevention Associated with Migraine Burden Improvements According to TRIUMPH Studyhttps://practicalneurology.com/news/emgality-treatment-for-migraine-prevention-associated-with-migraine-burden-improvements-according-to-triumph-study/2470217/Initial results from an ongoing study demonstrated greater improvements in migraine burden for patients who initiated or switched to Emgality (galcanezumab; Lilly, Indianapolis, IN) treatment for a 3 month period compared w
- Alzheimer's Association Launches ALZ-NET Registry for Study of New Treatments for Alzheimer Disease in Real-World Settinghttps://practicalneurology.com/news/alzheimers-association-launches-alz-net-registry-for-study-of-new-treatments-for-alzheimer-disease-in-real-world-setting/2469988/ALZ-NET is a national network of sites that will be collecting real-world evidence on people being treated with novel treatments approved by the Food and Drug Administration for the treatment of Alzheimer disease. This clinical registry is a model that has been used in other disease states, inclu
- Lamotrigine, Levetiracetam and Other Antiseizure Medications During Pregnancy Not Associated With Developmental Delays at Age 3 Yearshttps://practicalneurology.com/news/lamotrigine-levetiracetam-and-other-antiseizure-medications-during-pregnancy-not-associated-with-developmental-delays-at-age-3-years/2469520/According to a preliminary study, children born to women taking certain antiseizure medications (ASMs) for epilepsy during pregnancy had no higher risk of developmental delays at age 3 years when compared with children of women without epilepsy. The study involved 275 individuals
- New Drug Application Resubmission for Low-Dose Fenfluramine for Treatment of Seizures Associated With Dravet Syndromehttps://practicalneurology.com/news/new-drug-application-resubmission-for-zx008-fenfluramine-for-treatment-of-seizures-associated-with-dravet-syndrome/2468944/The Food and Drug Administration (FDA) has agreed that the new drug application (NDA) may be resubmitted for low-dose fenfluramine (Fintepla, previously known as ZX008; Zogenix, Emeryville, CA) without additional studies. Low-dose fenfluramine is investigational and being studied for treatment of
- Foslevodopa/Foscarbidopa Treatment for Advanced Parkinson Disease Associated with Significant Quality of Life Improvements According to Interim Analysis of Clinical Trial Datahttps://practicalneurology.com/news/foslevodopafoscarbidopa-treatment-for-advanced-parkinson-disease-associated-with-significant-quality-of-life-improvements-according-to-interim-analysis-of-clinical-trial-data/2470237/Patients with advanced Parkinson disease (aPD) treated with foslevodopa/foscarbidopa (ABBV-951, AbbVie; North Chicago, IL), a soluble formulation of levodopa/carbidopa prodrugs delivered as a 24-hour/day continuous subcutan
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- Fewer Anticonvulsant Prescriptions Filled Due to Pharmacy Closureshttps://practicalneurology.com/news/fewer-anticonvulsant-prescriptions-filled-due-to-pharmacy-closures/2470632/Pharmacy closures in communities in Colorado were associated with reductions in anticonvulsant medication prescription fills and days supplied with anticonvulsant medication, according to study results published in JAMA Neurology. Anticonvulsant medication nonadherence is associated with
- New Stroke Prevention Recommendations from AHA/ASA Publishedhttps://practicalneurology.com/news/new-stroke-prevention-recommendations-from-ahaasa-published/2470622/The American Heart Association and American Stroke Association (AHA/ASA) have published a new set of recommendations for the prevention of stroke. These new recommendations, which are published in the journal Stroke, are intended to serve as a resource for clinicians to integrate into their pract